Form 4 enVVeno Medical Corp For: Jun 11 Filed by: Duhay Francis

Fri, 12 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26640682.html

Form 4 enVVeno Medical Corp For: Jun 11 Filed by: Duhay Francis

Fri, 12 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26640682.html

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

Thu, 11 Jun 2026 11:17:00 -0400

si-local-file:///var/storage/secattach/20260611/26634229.html

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

Thu, 11 Jun 2026 11:17:00 -0400

si-local-file:///var/storage/secattach/20260611/26634229.html

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Tue, 02 Jun 2026 09:01:00 -0400

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9^that 4:00 PM ET

Register here

IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.

As part of the event, Mr.

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Tue, 02 Jun 2026 09:01:00 -0400

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9^that 4:00 PM ET

Register here

As part of the event, Mr.

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504589.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504589.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.

Fri, 15 May 2026 13:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26503345.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.

Fri, 15 May 2026 13:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26503345.html

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

Tue, 12 May 2026 09:02:00 -0400

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve

IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI

Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

Tue, 12 May 2026 09:02:00 -0400

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve

IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI

Watch the "What This Means" video here

enVVeno Medical Corporation (NVNO) Misses Q1 EPS by 565c

Thu, 07 May 2026 08:31:40 -0400

enVVeno Medical Corporation (NASDAQ: NVNO) reported Q1 EPS of ($5.89), $5.65 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on enVVeno Medical Corporation (NVNO) click here.

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

Thu, 07 May 2026 08:05:00 -0400

Company ended the first quarter with approximately $25 million in cash and investments

Capital on hand should fund operations through multiple key milestones into Q3 2027

Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe System

TAVVE site selection is underway with patient enrollment expected to commence later this year

IRVINE, CA / ACCESS Newswire / May 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the first quarter 2026, ending the quarter with approximately $25 million in

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

Thu, 07 May 2026 08:05:00 -0400

Company ended the first quarter with approximately $25 million in cash and investments

Capital on hand should fund operations through multiple key milestones into Q3 2027

Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe System

TAVVE site selection is underway with patient enrollment expected to commence later this year

Form 10-Q enVVeno Medical Corp For: Mar 31

Wed, 06 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26443862.html

Form 10-Q enVVeno Medical Corp For: Mar 31

Wed, 06 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26443862.html

Form 8-K enVVeno Medical Corp For: Apr 29

Wed, 29 Apr 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260429/26388726.html

Form 8-K enVVeno Medical Corp For: Apr 29

Wed, 29 Apr 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260429/26388726.html

enVVeno Medical gets FDA approval for venous valve study

Wed, 29 Apr 2026 08:08:49 -0400

enVVeno Medical Corporation (NASDAQ: NVNO) received FDA Investigational Device Exemption approval to proceed with a U.S. pivotal study of a non-surgical replacement venous valve, the company announced. The FDA approval represents the first such authorization for a non-surgical replacement venous valve study in the United States.

The Transcatheter Venous Valve Endoprosthesis pivotal study will evaluate the company's enVVe System for patients with severe deep Chronic Venous Insufficiency. Clinical site activation and patient enrollment are expected to begin later this year.

The study will be conducted in two stages. The first stage will include 10 patients, with 30-day safety results submitted to the

enVVeno Medical gets FDA approval for venous valve study

Wed, 29 Apr 2026 08:08:49 -0400

The study will be conducted in two stages. The first stage will include 10 patients, with 30-day safety results submitted to the

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

Wed, 29 Apr 2026 08:05:00 -0400

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial

Clinical site activation and patient enrollment expected to commence later this year

Large unmet clinical need for approximately 3 million U.S. patients with severe deep Chronic Venous Insufficiency

Potential multi-billion-dollar untapped U.S. market

Company has approximately $25 million in cash and investments to fund operations into Q3 2027

IRVINE, CA / ACCESS Newswire / April 29, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the U.S.

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

Wed, 29 Apr 2026 08:05:00 -0400

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial

Clinical site activation and patient enrollment expected to commence later this year

Large unmet clinical need for approximately 3 million U.S. patients with severe deep Chronic Venous Insufficiency

Potential multi-billion-dollar untapped U.S. market

Company has approximately $25 million in cash and investments to fund operations into Q3 2027

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Fri, 27 Mar 2026 08:30:00 -0400

Company accelerated development of the enVVe^® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation

Strong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestones

IRVINE, CA / ACCESS Newswire / March 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced financial results for the year ended December 31, 2025 and provided a corporate update highlighting its strategic focus on the development of its next-generation enVVe^® System.

Robert Berman, Chief Executive Officer of

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Fri, 27 Mar 2026 08:30:00 -0400

Company accelerated development of the enVVe^® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation

Strong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestones

Robert Berman, Chief Executive Officer of

StreetInsider.com News Articles

Form 4 enVVeno Medical Corp For: Jun 11 Filed by: Duhay Francis

Form 4 enVVeno Medical Corp For: Jun 11 Filed by: Duhay Francis

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Corporation (NVNO) Misses Q1 EPS by 565c

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

Form 10-Q enVVeno Medical Corp For: Mar 31

Form 10-Q enVVeno Medical Corp For: Mar 31

Form 8-K enVVeno Medical Corp For: Apr 29

Form 8-K enVVeno Medical Corp For: Apr 29

enVVeno Medical gets FDA approval for venous valve study

enVVeno Medical gets FDA approval for venous valve study

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System